olaparib + vorinostat

Olaparib + vorinostat is an investigational combination therapy consisting of two small molecule drugs, olaparib and vorinostat. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that blocks the PARP enzyme involved in DNA repair, leading to accumulation of DNA damage and cancer cell death. Vorinostat is a histone deacetylase (HDAC) inhibitor that interferes with the function of HDAC enzymes, resulting in altered gene expression and impaired DNA repair mechanisms. The rationale for combining these agents is to synergistically inhibit cancer cell ability to repair DNA damage by targeting two distinct pathways—PARP-mediated base excision repair and HDAC-mediated chromatin remodeling—thereby enhancing cytotoxicity against tumor cells. This combination has been studied primarily in early-phase clinical trials for relapsed/refractory or metastatic breast cancer as well as refractory lymphomas, often in conjunction with high-dose chemotherapy regimens or autologous stem cell transplantation[1][3][6]. Preclinical studies have demonstrated synergistic cytotoxic effects when both drugs are used together[5].

Brand names

LynparzaZolinza

Other names

suberoylanilide hydroxamic acid